Skip to main content
Premium Trial:

Request an Annual Quote

Allergy Dx Technology Deal Reached by ALK, Rellergen

NEW YORK (360Dx) – ALK will market Rellergen Biotech's allergy diagnostic technology in China as part of a deal announced today.

The tool called Bio-IC is a laboratory-on-a-chip-based technology that uses a blood sample on a disposable cartridge to screen up to 20 different allergens simultaneously, including food allergies. The system also includes compact screening and analysis apparatus.

Under the terms of the deal, ALK, based in Denmark, will market Bio-IC to more than 190 hospitals in China. Financial and other terms of the agreement were not disclosed.

Taiwanese firm Agnitio Biotech originally developed Bio-IC and being commercialized in China by its sister company Rellergen, which is setting up a local manufacturing facility. Chinese regulators approved the technology as an in vitro device in 2015, ALK and Rellergen said.